{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:30:19Z","timestamp":1790116219961,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10620-022-07582-w","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T14:34:04Z","timestamp":1655130844000},"page":"385-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Upadacitinib Is Safe and Effective for Crohn\u2019s Disease: Real-World Data from a Tertiary Center"],"prefix":"10.1007","volume":"68","author":[{"given":"Cindy","family":"Traboulsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Silfen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina G.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"5","key":"7582_CR1","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1053\/j.gastro.2020.04.034","volume":"160","author":"TL Parigi","year":"2021","unstructured":"Parigi TL, D\u2019Amico F, Danese S. Upadacitinib for crohn\u2019s disease and ulcerative colitis treatment: hitting the selective JAKpot. Gastroenterology. 2021;160:1472\u20131474. https:\/\/doi.org\/10.1053\/j.gastro.2020.04.034.","journal-title":"Gastroenterology."},{"key":"7582_CR2","unstructured":"Drug Approval Package: RINVOQ. Accessed September 4, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000TOC.cfm"},{"key":"7582_CR3","unstructured":"RINVOQ\u00ae (upadacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2019. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf"},{"issue":"8","key":"7582_CR4","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology. 2020;158:2123-2138.e8. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.047.","journal-title":"Gastroenterology."},{"key":"7582_CR5","unstructured":"Search of: upadacitinib | Crohn Disease | Phase 3 - List Results - ClinicalTrials.gov. Accessed September 22, 2021. https:\/\/clinicaltrials.gov\/ct2\/results?term=upadacitinib&cond=Crohn+Disease&age_v=&gndr=&type=&rslt=&phase=2&Search=Apply"},{"key":"7582_CR6","doi-asserted-by":"publisher","first-page":"S021","DOI":"10.1093\/ecco-jcc\/jjab075.022","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Danese S, Zhou W. OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study. J Crohns Colitis. 2021;15:S021\u2013S022.","journal-title":"J Crohns Colitis."},{"key":"7582_CR7","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.14309\/01.ajg.0000776300.15953.f6","volume":"116","author":"S Danese","year":"2021","unstructured":"Danese S, Vermeire S, Zhou W. S692 Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 U-ACHIEVE study. Am J Gastroenterol. 2021;116:S312\u2013S313.","journal-title":"Am J Gastroenterol."},{"key":"7582_CR8","unstructured":"AbbVie. Data on File: ABVRRT173267."},{"issue":"10","key":"7582_CR9","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675\u20132684. https:\/\/doi.org\/10.1002\/art.38745.","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"7582_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80:304\u2013311. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510.","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"7582_CR11","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020;158:2139-2149.e14. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.030.","journal-title":"Gastroenterology."},{"issue":"18","key":"7582_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2017;376:1723\u20131736. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"New Engl J Med."},{"issue":"9","key":"7582_CR13","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","volume":"12","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Ghosh S, Panes J et al. A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12:1485-1493.e2. https:\/\/doi.org\/10.1016\/j.cgh.2014.01.029.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"7582_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Sandborn WJ, Schreiber S et al. Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049\u20131059. https:\/\/doi.org\/10.1136\/gutjnl-2016-312735.","journal-title":"Gut."},{"issue":"9865","key":"7582_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet. 2013;381:451\u2013460. https:\/\/doi.org\/10.1016\/S0140-6736(12)61424-X.","journal-title":"The Lancet."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07582-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:50:16Z","timestamp":1675842616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07582-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7582"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07582-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DTR\u00a0has received grant support from from Takeda; and has served as a consultant for Abbvie, Altrubio, Allergan Inc., Arena Pharmaceuticals, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp\/Syneos, Connect BioPharma, GalenPharma\/Atlantica, Genentech\/Roche, Glycominds, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc. CT, FA, AS, TGR have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board at the University of Chicago (IRB20-1979).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}